Xiao‑I Corp Converts Note into $3.25 M ADS Offering Amid Audit‑Inspection Scrutiny

Xiao‑I Corp. announced that it will issue up to $3,250,000 of American Depositary Shares (ADSs) upon conversion of a convertible promissory note due 2027. Each ADS represents 60 ordinary shares with a par value of $0.00005 per share and will trade on Nasdaq under the ticker “AIXI.”

The prospectus supplement does not disclose a specific offering price per ADS, the exact number of ADSs to be issued, the underwriting discount, or the net proceeds after fees. What is clear is the gross proceeds ceiling of $3.25 million – a figure that mirrors the note’s principal amount. The filing also omits any overallotment (greenshoe) option and provides no closing date.

Pricing versus any prior range – The earlier registration statement did not publish a price range for this conversion‑linked offering, so investors lack a benchmark to gauge whether the final terms are generous or conservative. In the absence of a disclosed price, market participants will likely look to the last reported trading price of $15.47 per ADS on May 22 2026 (versus a $1.95 close on April 7 2026) as a reference point, though the filing makes no explicit connection.

Use of proceeds – The supplement offers no detailed allocation of the $3.25 million. The only guidance comes from the risk‑factor section, which warns that “the total proceeds from the note sale are limited to US$3,000,000, with estimated offering expenses of $10,000, potentially constraining the company’s use of funds.” Consequently, readers must assume the cash will support general corporate purposes, but the filing does not confirm any specific projects or debt repayment plans.

Underwriting syndicate – UBS is identified as the sole underwriter, shouldering the entire placement. No other banks or placement agents appear in the document, a fact that heightens execution risk given the modest size of the offering.

Key risk factors – The filing spotlights several concerns that loom over the transaction:

• HFCAA inspection risk – If the PCAOB cannot inspect Xiao‑I’s auditors for two consecutive years, the company’s securities could be barred from U.S. exchanges, triggering a delisting.
• Auditor identification risk – Both auditors are not on the PCAOB‑identified list, raising the possibility of denied or delayed inspections.
• Cross‑border audit access – Working papers reside in Singapore, and Chinese authorities may need to approve PCAOB access, adding uncertainty.
• Limited proceeds – With gross proceeds capped at $3 million and expenses estimated at $10,000, the cash cushion is thin.
• Conversion dilution – The note’s conversion into ADSs will increase the share count, potentially diluting existing holders.
• Single‑lender concentration – The note was sold to a single lender, concentrating financing risk.

Market context – The offering arrives as the broader IPO market remains cautious, and secondary‑type financings such as convertible note conversions have become a favored route for emerging‑market firms seeking U.S. capital without a full public offering. Analysts have noted that companies with exposure to China face heightened scrutiny under the Holding Foreign Companies Accountable Act, a theme that reverberates throughout Xiao‑I’s risk disclosures.

In sum, Xiao‑I’s $3.25 million ADS conversion marks a modest but strategically significant infusion of capital, albeit one shrouded in opacity regarding pricing and net proceeds. The filing’s emphasis on audit‑inspection hurdles and limited cash resources suggests that the company’s next moves will be closely watched by investors wary of regulatory headwinds and dilution risk.